Clinical Trial Update: AURORA: A Study for the Efficacy and Safety of Cenicriviroc (CVC) for the Treatment of Liver Fibrosis in Adults With Nonalcoholic Steatohepatitis (NASH) [Phase 3]

View source ↗

Summary

Phase 3 trial for cenicriviroc (CVC) in adults with nonalcoholic steatohepatitis was terminated; results posted in 2022.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Nonalcoholic Steatohepatitis

Drugs mentioned

• Cenicriviroc (cenicriviroc)

Snippet

Sponsor: Tobira Therapeutics, Inc. | Conditions: Nonalcoholic Steatohepatitis | Phase 3 | Status: TERMINATED | Results posted: 2022-03-10